ZA200501054B - Transplant acceptance inducing cells of monocytic origin and their preparation and use. - Google Patents

Transplant acceptance inducing cells of monocytic origin and their preparation and use.

Info

Publication number
ZA200501054B
ZA200501054B ZA200501054A ZA200501054A ZA200501054B ZA 200501054 B ZA200501054 B ZA 200501054B ZA 200501054 A ZA200501054 A ZA 200501054A ZA 200501054 A ZA200501054 A ZA 200501054A ZA 200501054 B ZA200501054 B ZA 200501054B
Authority
ZA
South Africa
Prior art keywords
inducing cells
transplant
preparation
monocytic origin
transplant acceptance
Prior art date
Application number
ZA200501054A
Other languages
English (en)
Inventor
Bernd Kremer
Friedrich Karl
Fred Fandrich
Maren Ruhnke
Original Assignee
Blasticon Biotech Forschung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blasticon Biotech Forschung filed Critical Blasticon Biotech Forschung
Publication of ZA200501054B publication Critical patent/ZA200501054B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ZA200501054A 2002-07-12 2005-02-04 Transplant acceptance inducing cells of monocytic origin and their preparation and use. ZA200501054B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10231655A DE10231655A1 (de) 2002-07-12 2002-07-12 Transplantat-Akzeptanz induzierende Zellen monozytären Ursprungs, sowie deren Herstellung und Verwendung

Publications (1)

Publication Number Publication Date
ZA200501054B true ZA200501054B (en) 2005-08-30

Family

ID=30009939

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA200501054A ZA200501054B (en) 2002-07-12 2005-02-04 Transplant acceptance inducing cells of monocytic origin and their preparation and use.
ZA200601074A ZA200601074B (en) 2002-07-12 2006-02-07 Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA200601074A ZA200601074B (en) 2002-07-12 2006-02-07 Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations

Country Status (18)

Country Link
US (1) US20060286670A1 (enExample)
EP (2) EP1557462B1 (enExample)
JP (1) JP2005532803A (enExample)
CN (1) CN100523176C (enExample)
AT (2) ATE309331T1 (enExample)
AU (1) AU2003250939B2 (enExample)
BR (1) BR0312693A (enExample)
CA (1) CA2492383A1 (enExample)
DE (3) DE10231655A1 (enExample)
DK (2) DK1492869T3 (enExample)
ES (3) ES2252696T3 (enExample)
IL (3) IL166021A0 (enExample)
NO (1) NO20050719L (enExample)
PT (2) PT1557462E (enExample)
RU (1) RU2370535C2 (enExample)
SI (3) SI1492869T1 (enExample)
WO (1) WO2004007701A1 (enExample)
ZA (2) ZA200501054B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10362002B4 (de) 2003-06-23 2006-10-12 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Adulte pluripotente Stammzellen
AU2004256154A1 (en) * 2003-07-11 2005-01-20 Blasticon Biotechnologische Forschung Gmbh Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical proparations
EP2514315A3 (en) * 2005-08-24 2012-11-07 Yeda Research and Development Co. Ltd. Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
US8470316B2 (en) 2005-10-14 2013-06-25 Chugai Seiyaku Kabushiki Kaisha Agents for suppressing damage to transplanted islets after islet transplantation
RU2450830C2 (ru) 2005-10-21 2012-05-20 Чугаи Сейяку Кабусики Кайся Средства для лечения кардиопатии
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
JP5754875B2 (ja) 2006-04-07 2015-07-29 国立大学法人大阪大学 筋再生促進剤
MX2009007830A (es) 2007-01-23 2009-10-07 Univ Shinshu Inhibidor de rechazo cronico.
TW201503898A (zh) 2008-06-05 2015-02-01 Chugai Pharmaceutical Co Ltd 神經浸潤抑制劑
WO2010049935A1 (en) * 2008-10-30 2010-05-06 Yeda Research And Development Co. Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
JP5436905B2 (ja) * 2009-03-26 2014-03-05 テルモ株式会社 シート状細胞培養物の製造方法
JP5667357B2 (ja) * 2009-11-30 2015-02-12 テルモ株式会社 シート状細胞培養物の製造方法
CN101812428A (zh) * 2010-04-26 2010-08-25 西北农林科技大学 一种乳腺上皮细胞的组织块种植方法
RS63800B1 (sr) 2010-05-28 2022-12-30 Chugai Pharmaceutical Co Ltd Poboljšanje antitumorskog odgovora t ćelije
DE102011004335A1 (de) 2011-02-17 2012-08-23 Thomas Grammel Verfahren zur Herstellung eines Vakzins
RU2508924C1 (ru) * 2013-02-21 2014-03-10 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" Способ профилактики и лечения отторжения почечного трансплантата
JP5727665B2 (ja) * 2014-12-11 2015-06-03 テルモ株式会社 シート状細胞培養物の製造方法
JP5893786B2 (ja) * 2015-04-02 2016-03-23 テルモ株式会社 シート状細胞培養物の製造方法
KR102769850B1 (ko) * 2015-07-03 2025-02-20 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 조절 t 세포를 수득하는 방법 및 이의 용도
JP6903866B2 (ja) * 2016-01-27 2021-07-14 国立大学法人 熊本大学 血液由来単球の増殖誘導方法
JP6140322B2 (ja) * 2016-02-24 2017-05-31 テルモ株式会社 シート状細胞培養物の製造方法
JP6490738B2 (ja) * 2017-04-28 2019-03-27 テルモ株式会社 シート状細胞培養物の製造方法
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
WO2019078344A1 (ja) 2017-10-20 2019-04-25 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
TWI822728B (zh) 2018-01-31 2023-11-21 加藤元一 含有il-6抑制劑的哮喘治療劑
JP6657452B2 (ja) * 2019-02-27 2020-03-04 テルモ株式会社 シート状細胞培養物の製造方法
AU2020259884A1 (en) 2019-04-17 2021-10-07 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
JP7002497B2 (ja) * 2019-06-20 2022-01-20 テルモ株式会社 シート状細胞培養物の製造方法
JP6872051B2 (ja) * 2020-02-05 2021-05-19 テルモ株式会社 シート状細胞培養物の製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766920A (en) * 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US9068164B1 (en) * 1995-02-02 2015-06-30 Tristem Trading (Cyprus) Limited Method of preparing an undifferentiated cell
US7112440B2 (en) * 1995-02-02 2006-09-26 Ghazi Jaswinder Dhoot Method of increasing the relative number of CD45 low cells in a cell population
GB9502022D0 (en) * 1995-02-02 1995-03-22 Abuljadayel Ilham M S A method for preparing lymphohaematopoietic progenitor cells
US7410773B2 (en) * 1995-02-02 2008-08-12 Ghazi Jaswinder Dhoot Method of preparing an undifferentiated cell
WO1996027392A1 (en) * 1995-03-08 1996-09-12 The Scripps Research Institute Antigen presenting system and methods for activation of t-cells
AU7499498A (en) * 1997-05-21 1998-12-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions for making dendritic cells from expanded populations ofmonocytes and for activating t cells
NL1017973C2 (nl) * 2000-05-10 2002-11-08 Tristem Trading Cyprus Ltd Inrichting.
AU2002224851A1 (en) * 2000-11-14 2002-05-27 Universite Libre De Bruxelles Generation and use of dendritic cells
TWI288779B (en) * 2002-03-28 2007-10-21 Blasticon Biotech Forschung Dedifferentiated, programmable stem cells of monocytic origin, and their production and use

Also Published As

Publication number Publication date
EP1492869B9 (en) 2006-05-24
EP1557462A2 (en) 2005-07-27
PT1644484E (pt) 2008-10-21
DE60302231T2 (de) 2006-07-20
WO2004007701A1 (en) 2004-01-22
SI1644484T1 (sl) 2009-02-28
AU2003250939B2 (en) 2008-05-22
PT1557462E (pt) 2008-06-18
EP1557462A3 (en) 2006-02-01
CN100523176C (zh) 2009-08-05
RU2005103627A (ru) 2005-08-27
DK1492869T3 (da) 2006-03-06
DE10231655A1 (de) 2004-02-26
DK1557462T3 (da) 2008-06-23
EP1492869A1 (en) 2005-01-05
AU2003250939A1 (en) 2004-02-02
DE60320009D1 (de) 2008-05-08
DE60302231D1 (de) 2005-12-15
EP1492869B1 (en) 2005-11-09
CN1681918A (zh) 2005-10-12
HK1071586A1 (en) 2005-07-22
SI1557462T1 (sl) 2008-08-31
ES2310711T3 (es) 2009-01-16
ZA200601074B (en) 2007-11-28
EP1557462B1 (en) 2008-03-26
IL172854A0 (en) 2006-06-11
ES2304647T3 (es) 2008-10-16
CA2492383A1 (en) 2004-01-22
RU2370535C2 (ru) 2009-10-20
NO20050719L (no) 2005-04-04
DE60320009T2 (de) 2009-05-20
ATE390480T1 (de) 2008-04-15
ATE309331T1 (de) 2005-11-15
IL166021A (en) 2010-05-17
SI1492869T1 (sl) 2006-04-30
JP2005532803A (ja) 2005-11-04
BR0312693A (pt) 2005-04-26
IL166021A0 (en) 2006-01-15
US20060286670A1 (en) 2006-12-21
ES2252696T3 (es) 2006-05-16

Similar Documents

Publication Publication Date Title
IL166021A0 (en) Trabsolant acceptance inducing cells of monocytic origin and their preparation and use
IL195338A0 (en) Optimized fc variants and methods for their generation
UA92505C2 (ru) Композиции на основе антитела против cd3
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
IL244803B (en) Human anti-beta antibodies and their use
PL1699822T3 (pl) Białka fuzyjne IL-7 z częściami przeciwciała, ich otrzymywanie oraz ich zastosowanie
NZ588674A (en) Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
MA30497B1 (fr) Anticorps et immunco-conjugues, et leurs utilisations.
MXPA03004793A (es) Roedores transgenicos transcromosomales para elaborar anticuerpos humnanos.
MY147217A (en) Antibody molecules having specificity for human il-06
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело
EP1513397A4 (en) Transgenic mammals capable of producing human antibodies
YU68602A (sh) Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje
BR0313135A (pt) Epìtopos de células t em eritropoietina
EA200800601A1 (ru) Связывающие fas антитела
AU2003259750A8 (en) Methods and compositions for targeting secretory lysosomes
TW200621718A (en) Novel co-crystals
EP2270054A3 (en) Anti-idiotype antibodies of the human monoclonal antibody SC-1, and their production and use
MY142798A (en) Methods for preventing glyconoylation of proteins
TW200519206A (en) Methods for producing novel medaka and novel medaka
NO20053829D0 (no) Fremgangsmate og intermediater for fremstilling av olanzapin.
LT2001122A (en) Method of propagation by layering